Journal article
Alteplase in Acute Ischemic Stroke: Putting the Guidelines into Practice
CNS drugs, Vol.28(11), pp.1035-1045
11/2014
DOI: 10.1007/s40263-014-0204-0
PMID: 25326784
Abstract
Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
Details
- Title: Subtitle
- Alteplase in Acute Ischemic Stroke: Putting the Guidelines into Practice
- Creators
- Nandakumar Nagaraja - Division of Cerebrovascular Diseases, Department of Neurology University of Iowa Carver College of Medicine 200 Hawkins Drive, 2148 RCP Iowa City IA 52242 USAHarold Adams Jr - Division of Cerebrovascular Diseases, Department of Neurology University of Iowa Carver College of Medicine 200 Hawkins Drive, 2148 RCP Iowa City IA 52242 USA
- Resource Type
- Journal article
- Publication Details
- CNS drugs, Vol.28(11), pp.1035-1045
- Publisher
- Springer International Publishing; Cham
- DOI
- 10.1007/s40263-014-0204-0
- PMID
- 25326784
- ISSN
- 1172-7047
- eISSN
- 1179-1934
- Language
- English
- Date published
- 11/2014
- Academic Unit
- Neurology; Iowa Neuroscience Institute
- Record Identifier
- 9984020638102771
Metrics
20 Record Views